View all newsletters
Receive our newsletter - data, insights and analysis delivered to you
  1. News
December 1, 2021

GreenLight and IAVI partner for Phase I trial of Covid-19 vaccine in Africa

The collaboration aims to expand and speed up access to mRNA vaccines for low-income countries across the world.

GreenLight Biosciences has collaborated with non-profit scientific research organisation International AIDS Vaccine Initiative (IAVI) for a Covid-19 vaccine trial in Africa.

Free Report
img

Build resilience in the face of COVID-19 disruption

COVID-19 has already affected our lives forever. The way we work, shop, eat, seek medical advice, and socialize will all be different in the future. Quite how different remains to be seen, but all industries must plan for multiple eventualities. Are you interested in actionable insights on the business challenges induced by the pandemic? GlobalData's cross-sector report analyzes the significance of this major disruptive theme across industry verticals. It provides side-by-side research of alternative datasets to present you with unique quantitative analysis of the effects of COVID-19 and how these differ across sectors. Additionally, it offers qualitative analysis of each sector and analyzes COVID-19’s impact on leading companies. Whatever your company’s imminent strategic plans, the long-lasting impact of COVID-19 must not be overlooked. Find out how to futureproof your business operations – download our report today.
by GlobalData
Enter your details here to receive your free Report.

Through this collaboration, the company will be able to advance its messenger RNA (mRNA) vaccine candidate for Covid-19.

It also aims to expand and speed up access to mRNA vaccines to prevent Covid-19, specifically for use in low-income countries across the world.

For the Phase I clinical trial, the company will provide its Covid-19 vaccine candidate. The trial is planned to begin in the first quarter of next year.

GreenLight will also prepare for large-scale manufacturing of the vaccine.

GreenLight CEO Andrey Zarur said: “There is an urgent need to develop vaccines in Africa, for Africa. Our vaccine trial, in partnership with IAVI, will open the way to make vaccines that are available to everybody, not just citizens of rich countries.

“If we don’t vaccinate the world quickly, then the ongoing emergence of new variants could compromise the tremendous progress made so far in the Covid-19 response.”

Once research sites and clinical research partners in Africa are finalised, the trial is expected to begin after receiving ethical and regulatory approvals.

GreenLight and IAVI aim to ensure the effectiveness and suitability of the vaccine candidate for African populations by engaging the country’s clinical investigators and communities previously affected by Covid-19.

IAVI president and CEO Mark Feinberg said: “Only about 6% of people in low-income countries have been vaccinated against Covid-19. This situation leaves hundreds of millions of people vulnerable to severe disease and could lead to the continued emergence of more dangerous viral variants.

“It is crucial for vaccine development to focus on overcoming inequities in access to SARS-CoV-2 vaccines and address the still unmet needs of low- and middle-income countries, which have mainly had to rely on imported vaccines developed elsewhere when they are available at all.”

In September, Gritstone dosed the first subject in a Phase I clinical trial to assess the ability of its self-amplifying mRNA (SAM) vaccine for Covid-19.

Related Companies

Free Report
img

Build resilience in the face of COVID-19 disruption

COVID-19 has already affected our lives forever. The way we work, shop, eat, seek medical advice, and socialize will all be different in the future. Quite how different remains to be seen, but all industries must plan for multiple eventualities. Are you interested in actionable insights on the business challenges induced by the pandemic? GlobalData's cross-sector report analyzes the significance of this major disruptive theme across industry verticals. It provides side-by-side research of alternative datasets to present you with unique quantitative analysis of the effects of COVID-19 and how these differ across sectors. Additionally, it offers qualitative analysis of each sector and analyzes COVID-19’s impact on leading companies. Whatever your company’s imminent strategic plans, the long-lasting impact of COVID-19 must not be overlooked. Find out how to futureproof your business operations – download our report today.
by GlobalData
Enter your details here to receive your free Report.

NEWSLETTER Sign up Tick the boxes of the newsletters you would like to receive. Key drug pipeline and competitive landscape changes based on the latest clinical activity, sent every Tuesday. Curated analysis and data-driven insights on clinical trials strategy and operations, sent every Thursday. The pharmaceutical industry's most comprehensive news and information delivered every month.
I consent to GlobalData UK Limited collecting my details provided via this form in accordance with the Privacy Policy
SUBSCRIBED

THANK YOU

Thank you for subscribing to Clinical Trials Arena